B2RLaw has advised Ambulero, Inc., a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease, on its receipt of up to USD 5.5 million in financing from Orphinic Scientific. Orphinic Scientific was advised by solo practitioner Stan Komorowski.
Ambulero is a 2019 spin-off of the University of Miami co-founded by Robert Buchanan, Randy Berholtz, Omaida Velazquez, and Jun Zhao-Liu. It holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. Omaida C. Velazquez and Jun Zhao-Liu.
With offices in Warsaw and Palo Alto, California, Orphinic Scientific is a drug development and investment company focused on mid-market opportunities and orphan drugs in late preclinical research and Phase 1 or 2.
According to B2RLaw, as part of the investment “Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. z o.o.) that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The disease is rare in the US but more common in certain parts of Central and Eastern Europe.”
B2RLaw’s team was led by Partner Szymon Syp and included Senior Associate Iga Wojtczak – Opala and Junior Associate Jakub Niemiec.
